98%
921
2 minutes
20
Angelman Syndrome (AS) is a neurodevelopmental disorder with severe symptoms and associated comorbidities. It is caused by the inactivity or lack of the UBE3a gene. Symptoms of the syndrome include intellectual disability and developmental delay. The current study investigated sleep disturbances (SD) in children and adolescents with AS, associations between SD and possible predictors of SD. Variables examined included age, gender, newborn and infancy history, challenging behavior, type of therapy received, genetic type of AS, and seizures. The sample included data from 109 participants with a mean age of 8.21, accessed via the Global Angelman Syndrome Registry. Chi-square tests were carried out to assess the associations between the variables and a logistical regression was carried out to assess the possible predictors of SD. Associations were found between SD and certain repetitive behaviors: slapping walls, focal hand movements, and agitation at new situations. From these associations, a regression formed a predictive model for sleep disturbances. The findings of this research demonstrated the importance of investigating the relationship between sleep disturbances and challenging behavior in children and adolescents with AS and the need for further research in this area.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.sleep.2024.07.033 | DOI Listing |
Alzheimers Dement
September 2025
School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, New South Wales, Australia.
Introduction: Risperidone is approved for behaviors and psychological symptoms of dementia (BPSD), despite modest efficacy and known risks. Identifying responsive symptoms, treatment modifiers, and predictors is crucial for personalized treatment.
Method: A one-stage individual participant data meta-analysis of six randomized controlled trials (risperidone: n = 1009; placebo: N = 712) was conducted.
Nihon Eiseigaku Zasshi
September 2025
Department of Hygiene, Public Health and Preventive Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Objective: In this study, we aimed to examine the relationship between the Eating Assessment Tool-10 (EAT10) score, a screening index for dysphagia, and the Epworth Sleepiness Scale (ESS) score, which evaluates daytime sleepiness in Japanese workers.
Method: A cross-sectional study of 496 workers (454 men and 42 women) at two business locations in Japan was conducted from November 2021 to June 2022. Dysphagia was assessed using the score of EAT10, a self-administered questionnaire.
J Pain
September 2025
Department of Orthopaedic Surgery, Duke University School of Medicine, Durham, NC, USA; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
In this longitudinal cohort study, we used nationally representative data from the U.S. National Health Interview Survey (n = 7,826 for chronic pain; n = 9,195 for high-impact chronic pain [HICP]) to examine the association of trouble sleeping and tiredness with 1-year incidence of chronic pain and HICP in U.
View Article and Find Full Text PDFSleep Med Rev
August 2025
Department of Developmental Neuroscience, IRCCS Stella Maris Foundation, Viale Del Tirreno. 341/A/B/C, Calambrone, Pisa, 56128 Italy; Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Via Savi 10, 56126, Pisa, Italy.
Melatonin is known to be effective in improving sleep in pediatric patients affected by neurological and psychiatric conditions. However, no guidelines exist advising the most effective treatment schedule. This systematic review and meta-analysis aimed to identify the dose, time of administration and treatment duration associated with the maximal treatment efficacy.
View Article and Find Full Text PDFDermatol Ther (Heidelb)
September 2025
Department of Dermatology, Kyoto University, Kyoto, Japan.
Atopic dermatitis (AD) is a chronic inflammatory disease characterized by eczematous skin lesions, intense pruritus, skin pain, sleep disruption, and mental health disturbances. There remains a need for a therapeutic option that delivers durable efficacy, safety, and convenient dosing across the AD patient population. This review provides an overview of AD pathogenesis driven by T-cell imbalance and describes a novel therapeutic option targeting the OX40 receptor, a costimulatory molecule expressed specifically on activated T cells.
View Article and Find Full Text PDF